MPT0E028 is an orally active and selective inhibitor of HDAC (IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2, and HDAC6, respectively). MPT0E028 has good anticancer activity. MPT0E028 decreases the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma.

1338320-94-7

C17H16N2O4S

344.39

MPT0E028

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years